Topical PTH (1-34) is a novel, safe and effective treatment for XXXX : a randomized self-controlled trial and an open trial.

@entity1 @entity2771 @entity137 @entity1569 @entity460 @entity272 @entity5200
BACKGROUND: There continues to be a need to develop new pharmacological approaches for treating the common @entity272 . @entity1 skin produces parathyroid hormone related peptide. This peptide is a potent inhibitor of epidermal cell growth. OBJECTIVES: A programme was initiated to determine whether an agonist of this peptide's receptor, PTH (1-34), could be developed as a drug to treat @entity1569 . METHODS: PTH (1-34) was formulated in Novasome A cream. Fifteen adult @entity1 with chronic @entity1569 who had failed to respond to at least one standard treatment were enrolled in a randomized double-blinded placebo self-controlled trial. The @entity1 topically applied to a 25-cm2 psoriatic lesion 0.1 g of either Novasome A cream or Novasome A cream that contained 20 microg of PTH (1-34) twice a day for 2 months. At the end of the double-blind study, @entity1 were enrolled in an open large area study. Ten @entity1 applied PTH (1-34) (50 microg per 0.1 g) once daily to their psoriatic lesions. The @entity1 were evaluated for their global improvement and @entity460 metabolism. RESULTS: Novasome A cream enhanced the percutaneous absorption of PTH (1-34) in @entity1 skin in comparison with formulations in @entity2771 or normal saline. Psoriatic lesions treated with PTH (1-34) showed marked improvement in scaling, erythema and induration. There was a 67.3% improvement in the global severity score for the lesion treated with PTH (1-34) compared with the placebo-treated lesion, which only showed a 17.8% improvement. Ten @entity1 topically applied PTH (1-34) on all of their lesions in a stepwise manner. A Psoriasis Area and Severity Index score analysis of all the @entity1 revealed improvement of 42.6% (P < 0.02). None of the @entity1 experienced hypercalcaemia or @entity5200 or developed any side-effect to the medication. CONCLUSIONS: @entity1 who were resistant to at least one standard therapy for @entity1569 had a remarkable improvement in their @entity1569 when they applied PTH (1-34) to their lesion(s). No untoward @entity137 was observed in any of the subjects. This pilot study suggests that topical PTH (1-34) is a safe and effective novel therapy for @entity1569 .
